Trial Profile
EFFICACY AND SAFETY OF NIVOLUMAB IN RECURRENT OR METASTATIC HEAD AND NECK CANCER (HNC) PATIENTS - JAPANESE REAL-WORLD DATA THROUGH CLINICAL CHART REVIEW -
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Feb 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 27 Jan 2022 Status changed from recruiting to completed.
- 02 Jul 2018 Status changed from not yet recruiting to recruiting.
- 18 May 2018 New trial record